key: cord-1002901-ymujkgc1 authors: Tuong, Linh-An C; Capucilli, Peter; Staicu, Mary; Ramsey, Allison; Walsh, Edward E; Mustafa, S Shahzad title: Graded Administration of Second Dose of Moderna and Pfizer-BioNTech COVID-19 mRNA Vaccine in Patients with Hypersensitivity to First Dose date: 2021-10-06 journal: Open Forum Infect Dis DOI: 10.1093/ofid/ofab507 sha: f4c3bc19face6911e9f05fc37fbea2ecd709b342 doc_id: 1002901 cord_uid: ymujkgc1 Two mRNA COVID-19 vaccines, Moderna and Pfizer-BioNTech, require two doses for maximum efficacy. This case series reports the safety and immunogenicity of a graded administration of the second dose of the Moderna or Pfizer-BioNTech COVID-19 vaccines in patients with immediate hypersensitivity reactions to the first dose. We report a case series of outpatients referred from the community to the Division of Allergy and Immunology at Rochester Regional Health (Rochester, New York) from January to May 2021 for evaluation of symptoms consistent with immediate hypersensitivity reactions to the first dose of the Moderna or Pfizer-BioNTech COVID-19 vaccine, who subsequently received their second dose through a graded administration protocol. Patients were evaluated with a thorough clinical history. Those with symptoms supportive of an immediate hypersensitivity reaction underwent unblinded skin prick and intradermal testing to vaccine components [polyethylene glycol (PEG) using Miralax (prick) and methylprednisolone acetate 0.4 4 mg/mL, 4 mg/mL (intradermal); polysorbate-80 using Refresh tears [undiluted (prick), 1:10 dilution (intradermal)], and the mRNA vaccine using vaccine overfill [undiluted (prick) and 1:10, 1:100 dilutions (intradermal)] 5 . Patients underwent graded administration of the vaccine (Table 1) regardless of skin testing results due to the uncertain predictive values of skin testing. Immunoglobulin G (IgG) titers to the SARS-CoV-2 Spike (S) protein were quantified by enzyme immunoassay using sera collected at least 2 weeks following the second dose and compared to 11 healthy adults (mean age 61.9 ± 5.9 years) who received either mRNA vaccines under standard schedules 15-57 days previously. Endpoint titers are expressed as the log2 dilution/ml. We evaluated 102 patients with suspected immediate hypersensitivity reactions to the first dose of the mRNA vaccines. Fifteen (Pfizer-BioNTech, n = 7; Moderna, n=8) patients had convincing objective and subjective histories of immediate hypersensitivity reactions and received dose 2 through a graded administration protocol (Table 2) , whereas 87 patients (females, n=85) did not have convincing symptoms and were advised to receive dose 2 without any special precautions, with none reporting subsequent reactions. All study patients were female between 21 and 64 years of age. Immediate symptoms included urticaria (n=7, 47%), lightheadedness (n=4, 27%), angioedema (n=4, 27%), nonurticarial rash (n=4, 27%), dyspnea (n=3, 20%), nausea/vomiting (n=3, 20%), all occurring 10 to 45 minutes after the first dose. One patient was treated with epinephrine. Skin testing was performed in 11 patients: 3 (27%) positive to components (PEG, polysorbate-80), 3 (27%) positive to vaccine (Moderna, n=2; Pfizer-BioNTech, n=1) and 1 (7%) positive to both (Pfizer-BioNTech). Four of 15 patients did not do skin testing due to lack of vaccine overflow (n=2) or dermatographia (n=2). No patients were premedicated for the second vaccine dose. Nine patients (60%) fully tolerated the protocol, while 1 (7%) had limited pruritus and 4 (27%) symptoms (cough, throat tightness, nausea, pruritus, or dyspnea) requiring treatment (albuterol and/or cetirizine). Following the final step of graded administration, two patients (13%) experienced anaphylaxis manifesting as throat tightness, cough and wheezing on chest auscultation in one and nausea with generalized urticaria in another. Both received one dose of epinephrine with prompt resolution of symptoms and were discharged home after an additional hour of monitoring. One of these patients had positive skin testing to the Moderna vaccine, but not to PEG or polysorbate-80. Mean serum IgG levels to the SARS-CoV-2 Spike protein following the second dose in 13 patients was not statistically different from healthy controls (log2 17.4 ± 1.1 vs. 16.7 ± 1.2). IgG was not checked in 2 patients due to lack of follow-up. In the study group and the healthy controls, there was one patient in each with previous COVID-19 infection. There is limited data on how best to proceed with the second mRNA COVID-19 vaccine dose in patients no studies on the safety or efficacy of this approach to date. We are the first to report graded administration of the second dose of the COVID-19 vaccine in patients with a reaction to the first dose and to demonstrate immunogenicity of this approach. Graded administration of other vaccines is well described and routinely performed as outpatients 9 . Due to the theoretical risk of rapid mRNA degradation, there is concern regarding the immunogenicity of split-dosing or graded administration of mRNA vaccines 4 Additionally, graded administration could obviate the need for skin testing to vaccine components or the vaccine itself, which has been previously suggested 4 The mechanism of hypersensitivity reaction to mRNA COVID-19 vaccines remains poorly understood. All patients in our study were female; this gender predominance is similar to previous reports 2 , 3 , 16 , the significance of which should be further evaluated. Reactions may be due to direct complement activation leading to mast cell degranulation, but may also involve an IgE-mediated mechanism 4 . If the sentinel immediate reaction is IgE-mediated, regardless of severity, then administering the second full dose puts the patient at risk for subsequent anaphylaxis. Although a recent study of patients with allergic reactions to the first dose tolerated an observed one-step second dose of the Pfizer-BioNTech vaccine with minimal or no symptoms 16 , 6 of our 15 patients experienced reactions during their graded administration, with two requiring epinephrine. Given the unknown mechanism and lack of tools to predict the severity of future immediate hypersensitivity reactions, a graded administration may be the most prudent method to facilitate introduction of the second dose of the vaccine in this setting through shared decision-making 17 , and may be more appealing to hesitant patients versus a single second dose. Regardless, administering a second dose as a single dose or two-step regimen might be appropriate for certain patients, and provide similar efficacy and safety to our graded dosing protocol. An important limitation to this study is that the diagnosis of immediate hypersensitivity to dose one of the mRNA vaccine was made based on subjective symptoms, in the absence of objective measurements such as serum tryptase. The authors used strict criteria to diagnose immediate hypersensitivity reactions, deeming the majority of patients appropriate to proceed with dose 2 with no special precautions. There was also an age difference between healthy controls versus study patients. Also, further studies would help to fully understand the immunogenicity of graded dosing. This case series is the first to report the safety and efficacy of a graded administration of the second COVID-19) Vaccinations-Statistics and Research. Our World Data Acute Allergic Reactions to mRNA COVID-19 Vaccines Reports of Anaphylaxis After Receipt of mRNA COVID-19 mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach What to do if you have an allergic reaction after getting a COVID-19 vaccine COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee Experts Discuss COVID-19-Variants and Vaccine Efficacy, Immunosuppressed Patients, and More COVID-19 Vaccination in Patients with Reported Allergic Reactions: Updated Evidence and Suggested Approach Adverse reactions to vaccines practice parameter 2012 update Administration of a Second Dose of the Moderna Vaccine After an Immediate Hypersensitivity Reaction With the First Dose: Two Case Reports COVID-19 vaccine testing & administration guidance for allergists/immunologists from the Canadian Society of Allergy and Clinical Immunology (CSACI) ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines -an EAACI-ARIA position paper Non-irritant concentrations for skin testing with SARS-CoV-2 mRNA Vaccine Polyethylene Glycol and Polysorbate Skin Testing in the Evaluation of COVID-19 Vaccine Reactions: Early Report Misdiagnosis of systemic allergic reactions to mRNA COVID-19 vaccines Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: Don't give up on the second dose! Allergy Epub ahead of print The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach Nausea (3, 5) , urticaria (5) Cetirizine (3, 5) , epinephrine